# Tenecteplase Compared to Alteplase for Patients With Large Vesel Oclusion Suspicion Before Thrombectomy

Study · id `cardio:ct-nct05626972` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05626972](<https://clinicaltrials.gov/study/NCT05626972>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05626972

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

## Technical summary

Registry record NCT05626972. Randomized; single masking; primary purpose treatment. Start 2022-05-27 (actual); primary completion 2023-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT05626972, source copy `cardio:ctgov-nct05626972-2022-11-25`, retrieved 2026-10-26)
- Started: 2022-05-27 (actual) (ClinicalTrials.gov record NCT05626972, source copy `cardio:ctgov-nct05626972-2022-11-25`, retrieved 2026-10-26)
- Primary completion: 2023-05 (anticipated) (ClinicalTrials.gov record NCT05626972, source copy `cardio:ctgov-nct05626972-2022-11-25`, retrieved 2026-10-26)
- Completion: 2024-05 (anticipated) (ClinicalTrials.gov record NCT05626972, source copy `cardio:ctgov-nct05626972-2022-11-25`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT05626972, source copy `cardio:ctgov-nct05626972-2022-11-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05626972-2022-11-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Tenecteplase Compared to Alteplase for Patients With Large Vesel Oclusion Suspicion Before Thrombectomy
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Tenecteplase
- Lead sponsor: Hospital Universitari Vall d'Hebron Research Institute
- Lead sponsor class: OTHER
- Collaborator: Instituto de Salud Carlos III
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Tenecteplase (`cardio:tenecteplase`)
- Registry intervention is a member of this class by a sourced record link: Fibrinolytic (clot-dissolving) drugs (`cardio:fibrinolytic-clot-dissolving-drugs`)
- Registry lists this organization as the lead sponsor: Hospital Universitari Vall d'Hebron Research Institute (`cardio:org-hospital-universitari-vall-d-hebron-research-institute`)
- Registry lists this organization as a collaborator: Instituto de Salud Carlos III (`cardio:org-instituto-de-salud-carlos-iii`)

## Provenance

Content hash: 01d3d76faf335987710225ad8aa258dbf13b74c603eb40ba4d4e501a2f4935e2
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
